Press releasePRNewswire
Edgewise Therapeutics
EWTX · NASDAQ
$39.75+$1.83 (+4.83%)TodayMarket closed ·
Prev close $37.92
Latest news
- Press releasePRNewswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Press releasePRNewswire
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
- Press releasePRNewswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Press releasePRNewswire
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
- Press releasePRNewswire
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
- Press releasePRNewswire
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
- Press releasePRNewswire
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
- Press releasePRNewswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- NewsVandana Singh
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
- Press releaseGlobe Newswire
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releasePRNewswire
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
- Press releasePRNewswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- NewsAvi Kapoor
Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today
- News
Edgewise To Sell Its Muscular Dystrophy Business To Servier For $1.55B In Cash Up Front And Up To $1.1B In Further Milestone Payments For Aggregate Potential Sum Of Up To $2.65B
- Press releasePRNewswire
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
- Press releasePRNewswire
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
- Press releasePRNewswire
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
- Press releasePRNewswire
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releasePRNewswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Press releasePRNewswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Press releasePRNewswire
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
- Press releasePRNewswire
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
- Press releasePRNewswire
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
- Press releasePRNewswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Press releasePRNewswire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
- Press releasePRNewswire
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
- Press releasePRNewswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- NewsAvi Kapoor
Gold Edges Lower; Omeros Shares Jump
- NewsAvi Kapoor
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
- NewsVandana Singh
Why Is Edgewise Therapeutics Stock Soaring Wednesday?
- NewsAvi Kapoor
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
- NewsAvi Kapoor
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.